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Abstract
Background: This case report describes a spontaneous tumor lysis syndrome due to a rare solid tumor.
Case presentation: A 65-year-old white woman had tumor lysis syndrome, which represent a dangerous oncological
emergency. This syndrome occurs usually with a hematological tumor, but in this case our patient had a solid tumor,
which was a rare extraskeletal osteosarcoma, localized in her pelvic region. She also had lung metastases and bilateral
hydronephrosis.
After spontaneous tumor lysis syndrome, she had acute renal insufficiency, which was treated with hemodialysis and
successively with rasburicase, Kayexalate (sodium polystyrene sulfonate), and febuxostat.
Conclusion: Tumor lysis syndrome represents an oncological emergency, which must be suspected and treated as
soon as possible.
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Background
Tumor lysis syndrome (TLS) is one of the major onco-
logical emergencies; disruption is caused by massive
tumor cell lysis in which the contents of the lysed tumor
cells are released into the bloodstream [1]. It is a poten-
tial fatal complication of the treatment of hematological
tumors and, less frequently, of solid aggressive tumors.
Hematologic malignancies comprise the vast majority of
TLS, which is believed to be secondary to treatment
sensitivity and rapid proliferative rates [2, 3]. Patients
with a solid tumor usually show TLS after intensive
chemotherapy (treatment-induced TLS), but sometimes
it can appear before the treatment (spontaneous TLS)
especially in cases of bulky tumors with wide necrotic
areas. TLS can alter the body’s homeostatic mechanisms
and cause hyperuricemia, hyperkalemia, hyperphospha-
temia, and uremia [4].
Extraskeletal osteosarcoma (ESOS) is a rare subtype of
osteosarcoma without attachment to bone or perios-
teum. It accounts for less than 4% of all osteosarcomas
and approximately 1 to 2% of all soft tissue sarcomas
(STSs) [5]. The clinical features of patients with this
tumor differ significantly from the clinical features of
patients with skeletal osteosarcoma, including older age,
propensity for axial tumors, and female preponderance.
Although ESOS has been found to develop in all
organs, the most common locations are limbs. In the
case of abdominal or pelvic lesions the diagnosis can be
very difficult, thus it requires confirmation after explora-
tory laparotomy and histopathology. Such tumors may
reach an enormous size before detection, because the
enlarging mass may not be associated with pain. ESOS
may be one of the differential diagnoses to be considered
in the case of calcified masses arising in retroperitoneal
space [5, 6].
In previous studies, the total number of patients
reported with both tumor lysis and sarcoma was five:
three males and two females and their age spanned from
9 years to 66 years. All of them had evidence of
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advanced and metastatic disease [5–10]. One patient
was reported to have normal baseline values of creatin-
ine and phosphorus, whereas another patient had
elevated baseline values of creatinine and lactate
dehydrogenase (LDH). Three cases were preceded by
chemotherapy; the other two cases were represented by
spontaneous TLS. All the cases taken in consideration
had baseline elevation of uric acid and phosphorus.
Clinical tumor lysis occurred more frequently in
patients with pre-treatment renal insufficiency than in
patients with normal renal function. The development of
uremia is correlated with high pre-treatment serum
LDH concentrations [4].
Case presentation
A 65-year-old white woman was hospitalized for a right
hypochondrium colicky pain radiating to the ipsilateral
subscapularis region. Her pain was not related to food
and posture. It appeared during the previous week and
persisted despite nonsteroidal anti-inflammatory medi-
cation. A clinical examination showed that her abdomen
was swollen in the right iliac fossa and the presence of
voluminous palpable mass that was hard, fixed to the
deep layers, and sore to touch.
An abdominal ultrasound (US) examination revealed
her liver with gallbladder stones, a heterologous formation
in her right iliac fossa with internal calcification, which
compressed the iliac vessels, and a bilateral hydronephrosis
more marked on the right than on the left.
Laboratory tests revealed significant alterations
(Table 1). Her blood pressure was above 180 mmHg. A
chest X-ray showed the presence of multiple metastases
placed in both lung fields. A total body computed tomog-
raphy scan (CT) without contrast confirmed the presence
of lung metastases, bilateral hydronephrosis, and a mass in
her right iliac fossa invading her ureter and her iliac artery.
There was also a mass in the right iliac mass but with
a reduced size in the left iliac fossa invading her psoas
muscle. The internal structure of the masses was
homogeneous, apart from the centrally located amorph-
ous high-attenuation areas. There was no fat inside the
lesion.
She underwent hemodialysis and infusion therapy with
rasburicase (Fasturtec ®; Table 1).
Prompt dialysis is necessary when treatment fails
to normalize electrolytes or establish urinary flow.
Hemodialysis removes excess circulating uric acid.
Before the dialysis our patient was hyperuricemic and oli-
guric. After the dialysis, we observed that she developed
diuresis, associated with the consequent resolution of
hyperuricemia, hyperazotemia, hyperphosphatemia, and
normalization of electrolytes.
After 10 days she underwent surgery. An exploration
of her abdominal cavity detected a retroperitoneal mass
in her right iliac region which involved the last ileal loop
besides compressing the iliac vessels and infiltrating her
ureter. Another mass in her left iliac fossa caused a
compression of the left iliac vessels and ureter without
infiltration. As a result of the inoperability of the mass
in her right iliac region, an ileotransversostomy was
performed with enucleation of the left mass and
cholecystectomy.
An histological examination performed on the mass
diagnosed an ESOS infiltrating her psoas muscle, her in-
ternal iliac artery, and her bladder wall. On macroscopic
examination the mass had a hard consistency, was
whitish-gray in color, and there were large central calci-
fied parts and areas of hemorrhagic-necrotic tissue. The
mass was osteoblastic histological type, consisting of
osteoblasts producing an osteoid material. The lesional
cells showed great cytological atypia, high mitotic activ-
ity, and permeative growth pattern (Fig. 1).
The tumor massively invaded our patient’s abdominal
cavity and metastasized in both lung fields. According to
these parameters, she was in a very poor prognostic sub-
group, due to a very bulky and high growth rate tumor.
This tumor was only partially resectable because she was
over 60-years old and showed multiple metastatic
lesions, multiorgan impairment, and increased alkaline







Alkaline phosphatase IU/l 1460 670 20–140
Urea nitrogen mg/dl 196.2 58.3 10–50
Creatinine mg/dl 7.89 1.36 0.60–1.50
Phosphorus mg/dl 4.9 4.2 2.6–4.5
Calcium mg/dl 7.5 7.7 8.5–10.5
Sodium mmol/l 144 136 135–145
Potassium mmol/l 6.1 4.2 3.4–4.8
Lactate dehydrogenase U/l 1120 870 110–210
Uric acid mg/dl 11.4 6.7 3.6–8.5
Fig. 1 Round and multinucleated cells separated by osteoid
material (×200)
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tissue masses with focal or massive areas of calcification
and no osseous involvement. Magnetic resonance (MR)
images showed intermediate signal intensity on T1-
weighted images and a low-to-hyperintense signal on
T2-weighted images.
The diagnosis of osteoblastic ESOS was confirmed by
the tumor localization within the soft tissue, without
attachment to bony structures, and the presence of abun-
dant osteoid. There was no history of radiation or trauma
in our patient, but there was an anamnestic finding of
hysterectomy just 6 months before the diagnosis of ESOS.
The most common presentation of ESOS is a gradually
enlarging mass that varies in size from 1 to 50 cm in
diameter and does not always imply pain. Very large and
bulky tumors often develop in the retroperitoneum
before their detection as in our case. Thus the presence
of metastatic lesions, the patient’s age, and the size were
the major prognostic factors; in addition, patients with
very large lesions have a worse clinical outcome.
Discussion
ESOS is a high-grade malignant mesenchymal neoplasm
with very aggressive behavior. The tumor is typically
located in the deep soft tissues, without attachment to
skeletal bones. The most common affected site is the
thighs, followed by upper extremities, retroperitoneum,
and buttocks.
The etiology of ESOS is essentially unknown, even
though there have been reported cases of radiation-
induced ESOS, a history of previous trauma, intra-
muscular injection at the tumor site, and malignant
transformation of myositis ossification. ESOS has also
been shown to develop in unusual sites, such as
mediastinum, hand, cerebellum, heart, skin, pleura,
larynx, scalp, tongue, penis, gallbladder, breast, and
mesentery.
The treatment of choice for ESOS is amputation or a
wide surgical resection of the tumor for local control
and to prevent a possible recurrence. Chemotherapy and
radiation therapy can be combined to surgery although
their role in neoadjuvant or adjuvant therapy has not
been clearly defined yet. Nevertheless, classical high-
grade ESOS still remains a very aggressive rare tumor
with a poor prognosis.
Our patient had a spontaneous TLS, with an acute
renal insufficiency, treated with hemodialysis (Table 1).
After this treatment, TLS was treated with rasburicase,
Kayexalate (sodium polystyrene sulfonate), abundant
hydration, and febuxostat (Fig. 1) [11, 12].
Risk factors for TSL include: (1) presence of bulky dis-
ease, particularly with pluri-metastatic sites (especially
abdominal metastases), bulky adenopathy, and hepatos-
plenomegaly; (2) high leucocyte count; (3) elevated pre-
treatment LDH; (4) elevated pre-treatment uric acid; (5)
compromised renal function; and (6) history of use of
potentially nephrotoxic drugs [7].
The most frequent serological alteration is: hyperuri-
cemia, hyperkalemia, hyperphosphatemia, and hypocal-
cemia. Both hyperuricemia and hyperphosphatemia
can evolve in renal failure and they can also cause
cardiologic complications. The contemporaneous pres-
ence of the two electrolytic alterations may cause a
fall in cardiologic function [8–10]. Hyperuricemia re-
sults from the release and breakdown of purine nu-
cleic acids. Uric acid is poorly soluble in water and,
when normal limits of excretion are surpassed, pre-
cipitation of crystals occurs in the renal tubules lead-
ing to renal insufficiency and, potentially, failure [13].
Malignant cells often have a higher phosphate con-
centration than normal cells. Rapid lysis can lead to
hyperphosphatemia when the normal homeostatic
mechanisms are overwhelmed. Excretion of phosphate
Fig. 2 Cause, prevention, and treatment of tumor lysis syndrome
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may be further impaired because of acute kidney in-
jury either from uric acid crystal deposition or from
tumor involvement of the kidneys [14]. In the setting
of hyperphosphatemia, calcium phosphate precipita-
tion may also occur in renal tubules, contributing fur-
ther to acute kidney injury [15]. Hyperphosphatemia
may also cause nausea, vomiting, diarrhea, lethargy,
or seizures. Hypocalcemia in TLS is a consequence of
hyperphosphatemia, causing calcium phosphate pre-
cipitation in tissues.
TLS may be clinically asymptomatic, but hyperkalemia
and hypocalcemia may cause neurologic, cardiovascular,
or muscular symptoms including seizures, arrhythmias
(typically with a longer QT space), and tetany. Hyperka-
lemia is a potentially life-threatening consequence of
TLS, occurring when large quantities of potassium are
released from necrotic tumor cells. Acute kidney injury,
if present, can worsen hyperkalemia. A rapid increase in
serum potassium levels may result in cardiac arrhythmia
and cardiac arrest [16–18].
In neoplastic patients, acute tumor lysis may be a
cause of acute renal failure (ARF) due to severe meta-
bolic derangement. Acute TLS has rarely been investi-
gated and most patients developed spontaneous and
oliguric ARF before therapy. The cause of renal failure is
now recognized as acute uric acid nephropathy, due to
increased uric acid production and hyperuricosuria
resulting from a high tumor cell turnover rate. A key
distinction between spontaneous tumor lysis and TLS is
the lack of hyperphosphatemia in the spontaneous form
occurring after therapy.
Search strategy
We searched PubMed/Medline, Scopus, Embase, and
Web of Sciences articles that focused on TLS in patients
with osteosarcomas published from 1960 to September
2016. The search methodology was adapted from scien-
tific search guidelines published in 2011.
Conclusions
Previous studies have shown a reduced incidence of
significant post-treatment hyperuricemia and hyperpho-
sphatemia as the most common laboratory abnormalities
associated with post-treatment ARF. Prospective investi-
gations are required to compare conservative treatment
with pre-emptive dialysis and to develop reliable clinical
profiles identifying patients at risk of developing renal
failure and increasing the potential of TLS.
Acute TLS often represents a fatal complication in
treated and non-treated tumors. A prompt treatment of
TLS in ESOS and in others tumor reduces complications
and can improve prognosis and quality of life (Fig. 2).
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